Medicure (MPH.V) Stock Price

Medicure Price

TSX·CLOSED
1.35CAD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 8.7% per year over the past 19 years to 28.86 M CAD. Earnings per share have declined at 21.5% per year over the last 11 years. Medicure's net margin stands at -24.6%, down from -3.3% several years earlier. The stock trades about 50% above its 52-week low.

Medicure stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Medicure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medicure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medicure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medicure Stock Price History
DateMedicure Price
8/10/20261.35 CAD
8/7/20261.35 CAD
8/6/20261.30 CAD
8/5/20261.30 CAD
8/4/20261.30 CAD
7/31/20261.30 CAD
7/30/20261.18 CAD
7/29/20261.04 CAD
7/28/20261.04 CAD
7/27/20261.04 CAD
7/23/20261.04 CAD
7/22/20261.13 CAD
7/21/20261.07 CAD
7/20/20261.07 CAD
7/17/20261.07 CAD
7/16/20261.07 CAD
7/15/20261.07 CAD
7/14/20261.07 CAD
7/13/20261.04 CAD
7/10/20261.06 CAD
7/9/20261.06 CAD
7/8/20261.29 CAD
7/7/20261.29 CAD
7/6/20261.29 CAD
7/3/20261.29 CAD
7/2/20261.29 CAD
6/30/20261.29 CAD
6/29/20261.28 CAD
6/26/20261.28 CAD
6/25/20261.28 CAD
6/24/20261.28 CAD
6/23/20261.25 CAD
6/22/20261.25 CAD
6/19/20261.20 CAD
6/18/20261.00 CAD
6/17/20261.00 CAD
6/16/20261.07 CAD
6/15/20261.07 CAD
6/12/20261.04 CAD
6/11/20261.04 CAD
6/10/20261.04 CAD
6/9/20261.04 CAD
6/8/20261.04 CAD
6/5/20261.08 CAD
6/4/20261.08 CAD
6/3/20261.11 CAD
6/2/20261.11 CAD
6/1/20261.16 CAD
5/29/20261.11 CAD
5/28/20261.11 CAD
5/27/20261.11 CAD
5/26/20261.10 CAD
5/25/20261.10 CAD
5/22/20261.10 CAD
5/21/20261.10 CAD
5/20/20261.20 CAD
5/19/20261.10 CAD
5/15/20261.19 CAD
5/14/20261.19 CAD
5/13/20261.15 CAD
5/12/20261.15 CAD
5/11/20261.18 CAD
5/8/20261.18 CAD
5/7/20261.18 CAD
5/6/20261.22 CAD
5/5/20261.22 CAD
5/4/20261.15 CAD
5/1/20261.05 CAD
4/30/20261.05 CAD
4/29/20260.95 CAD
4/28/20260.95 CAD
4/27/20260.95 CAD
4/24/20260.90 CAD
4/23/20261.35 CAD
4/22/20261.35 CAD
4/21/20261.35 CAD
4/20/20261.35 CAD
4/17/20261.35 CAD
4/16/20261.35 CAD
4/15/20261.35 CAD
4/14/20261.35 CAD
4/13/20261.35 CAD
4/10/20261.22 CAD
4/9/20261.22 CAD
4/8/20261.22 CAD
4/7/20261.22 CAD
4/6/20261.22 CAD
4/2/20261.12 CAD
4/1/20261.12 CAD
3/31/20261.12 CAD
3/30/20261.12 CAD
3/27/20261.12 CAD
3/26/20261.12 CAD
3/25/20261.12 CAD
3/24/20261.12 CAD
3/23/20260.95 CAD
3/20/20260.95 CAD
3/19/20260.95 CAD
3/18/20260.95 CAD
3/17/20260.95 CAD
3/16/20260.95 CAD
3/13/20260.95 CAD
3/12/20260.95 CAD
3/11/20260.95 CAD
3/10/20260.97 CAD
3/9/20260.97 CAD
3/6/20260.97 CAD
3/5/20260.97 CAD
3/4/20261.12 CAD
3/3/20261.12 CAD
3/2/20261.28 CAD
2/27/20261.23 CAD
2/26/20261.12 CAD
2/25/20260.95 CAD
2/24/20261.11 CAD
2/23/20261.11 CAD
2/20/20261.11 CAD
2/19/20261.12 CAD
2/18/20261.12 CAD
2/17/20261.12 CAD
2/13/20261.12 CAD
2/12/20261.12 CAD
2/11/20261.14 CAD
2/10/20261.14 CAD
2/9/20261.15 CAD
2/6/20261.15 CAD
2/5/20261.15 CAD
2/4/20261.15 CAD
2/3/20261.16 CAD
2/2/20261.16 CAD
1/30/20261.16 CAD
1/29/20261.16 CAD
1/28/20261.23 CAD
1/27/20261.23 CAD
1/26/20261.23 CAD
1/23/20261.23 CAD
1/22/20261.23 CAD
1/21/20261.32 CAD
1/20/20261.32 CAD
1/19/20261.15 CAD
1/16/20261.15 CAD
1/15/20261.15 CAD
1/14/20261.15 CAD
1/13/20261.18 CAD
1/12/20261.16 CAD
1/9/20261.16 CAD
1/8/20261.25 CAD
1/7/20261.14 CAD
1/6/20261.20 CAD
1/5/20261.14 CAD
1/2/20261.14 CAD
12/31/20251.14 CAD
12/30/20251.25 CAD
12/29/20251.25 CAD
12/24/20251.21 CAD
12/23/20251.30 CAD
12/22/20251.30 CAD
12/19/20251.25 CAD
12/18/20251.25 CAD
12/17/20251.25 CAD
12/16/20251.25 CAD
12/15/20251.11 CAD
12/12/20251.11 CAD
12/11/20251.11 CAD
12/10/20251.11 CAD
12/9/20251.11 CAD
12/8/20251.34 CAD
12/5/20251.34 CAD
12/4/20251.34 CAD
12/3/20251.34 CAD
12/2/20251.34 CAD
12/1/20251.34 CAD
11/28/20251.35 CAD
11/27/20251.10 CAD
11/26/20251.10 CAD
11/25/20251.04 CAD
11/24/20251.24 CAD
11/21/20251.30 CAD
11/20/20251.30 CAD
11/19/20251.43 CAD
11/18/20251.06 CAD
11/17/20251.29 CAD
11/14/20251.25 CAD
11/13/20251.29 CAD
11/12/20251.29 CAD
11/11/20251.29 CAD
11/10/20251.30 CAD
11/7/20251.16 CAD
11/6/20251.16 CAD
11/5/20251.16 CAD
11/4/20251.16 CAD
11/3/20251.16 CAD
10/31/20251.16 CAD
10/30/20251.27 CAD
10/29/20251.03 CAD
10/28/20251.20 CAD
10/27/20251.10 CAD
10/24/20251.09 CAD
10/23/20251.09 CAD
10/22/20251.09 CAD
10/21/20251.09 CAD
10/20/20251.09 CAD
10/17/20251.09 CAD
10/16/20251.10 CAD
10/15/20251.10 CAD
10/14/20251.10 CAD
10/10/20251.01 CAD
10/9/20251.01 CAD
10/8/20251.10 CAD
10/7/20251.10 CAD
10/6/20251.10 CAD
10/3/20251.10 CAD
10/2/20251.10 CAD
10/1/20251.10 CAD
9/30/20251.10 CAD
9/29/20251.10 CAD
9/26/20251.10 CAD
9/25/20251.15 CAD
9/24/20251.10 CAD
9/23/20251.10 CAD
9/22/20251.10 CAD
9/19/20251.10 CAD
9/18/20251.10 CAD
9/17/20251.10 CAD
9/16/20250.96 CAD
9/15/20251.00 CAD
9/12/20251.00 CAD
9/11/20251.12 CAD
9/10/20251.12 CAD
9/9/20251.12 CAD
9/8/20251.20 CAD
9/5/20251.12 CAD
9/4/20251.32 CAD
9/3/20251.32 CAD
9/2/20251.12 CAD
8/29/20251.15 CAD
8/28/20251.15 CAD
8/27/20251.15 CAD
8/26/20251.15 CAD
8/25/20251.05 CAD
8/22/20251.05 CAD
8/21/20251.05 CAD
8/20/20251.05 CAD
8/19/20251.05 CAD
8/18/20251.05 CAD
8/15/20251.15 CAD
8/14/20251.15 CAD
8/13/20251.15 CAD
Access this data via the Eulerpool API
Get Free API Key

Medicure Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
21.69 M CAD
-854,000.00 CAD
-922,000.00 CAD
Jan 1, 2024
21.91 M CAD
-2.74 M CAD
-1.04 M CAD
Jan 1, 2025
28.86 M CAD
-6.89 M CAD
-7.10 M CAD
Jan 1, 2026 (e)
43.94 M CAD
-2.55 M CAD
-4.17 M CAD
Jan 1, 2027 (e)
29.26 M CAD
-1.70 M CAD
2.19 M CAD
Jan 1, 2028 (e)
23.89 M CAD
-1.39 M CAD
-3.03 M CAD
Jan 1, 2029 (e)
20.16 M CAD
-1.17 M CAD
-3.13 M CAD
Jan 1, 2030 (e)
22.73 M CAD
-1.32 M CAD
-3.24 M CAD

Medicure Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 1:07 AM
 
REVENUEM CAD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CAD
EBITM CAD
EBIT MARGIN%
NET INCOMEM CAD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e2031e2032e
27.0029.0020.0011.0021.0023.0021.0021.0028.0043.0029.0023.0020.0022.0023.0020.00
-27.037.41-31.03-45.0090.919.52-8.70–33.3353.57-32.56-20.69-13.0410.004.55-13.04
85.1982.7660.0045.4557.1469.5761.9061.9039.2939.2939.2939.2939.2939.2939.2939.29
23.0024.0012.005.0012.0016.0013.0013.0011.0016.8911.399.047.868.649.047.86
3.00-1.00-10.00-7.00–1.00–-2.00-6.00-2.00-1.00-1.00-1.00-1.00-1.00-1.00
11.11-3.45-50.00-63.64–4.35–-9.52-21.43-4.65-3.45-4.35-5.00-4.55-4.35-5.00
43.003.00-19.00-6.00–1.00–-1.00-7.00-4.002.00-3.00-3.00-3.00-2.00-3.00
59.26-93.02-733.33-68.42––––600.00-42.86-150.00-250.00––-33.3350.00
15.6415.7915.0010.2510.2510.2510.4410.4410.4410.4410.4410.4410.4410.4410.4410.44
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medicure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medicure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medicure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medicure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medicure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medicure stock margins

The Medicure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medicure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medicure.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
58.46 %
-2.64 %
-3.34 %
Jan 1, 2022
69.69 %
5.17 %
5.92 %
Jan 1, 2023
62.48 %
-3.94 %
-4.25 %
Jan 1, 2024
59.75 %
-12.49 %
-4.74 %
Jan 1, 2025
40.71 %
-23.87 %
-24.60 %
Jan 1, 2026 (e)
40.71 %
-5.80 %
-9.50 %
Jan 1, 2027 (e)
40.71 %
-5.80 %
7.49 %
Jan 1, 2028 (e)
40.71 %
-5.80 %
-12.67 %

Medicure Stock Revenue, EBIT, Earnings per Share

The Medicure earnings per share therefore indicates how much revenue Medicure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.12 CAD
-0.06 CAD
-0.07 CAD
Jan 1, 2022
2.25 CAD
0.12 CAD
0.13 CAD
Jan 1, 2023
2.08 CAD
-0.08 CAD
-0.09 CAD
Jan 1, 2024
2.10 CAD
-0.26 CAD
-0.10 CAD
Jan 1, 2025
0.00 CAD
0.00 CAD
0.00 CAD
Jan 1, 2026 (e)
4.21 CAD
-0.24 CAD
-0.40 CAD
Jan 1, 2027 (e)
2.80 CAD
-0.16 CAD
0.21 CAD
Jan 1, 2028 (e)
2.29 CAD
-0.13 CAD
-0.29 CAD

Medicure business model & stock analysis

Medicure Inc. is a pharmaceutical company specializing in the development of medications for cardiovascular diseases. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Medicure SWOT Analysis

Strengths

Medicure Inc possesses several key strengths that contribute to its success in the pharmaceutical industry:

  • Strong portfolio of patented drugs
  • Experienced and knowledgeable research and development team
  • Established distribution networks and partnerships
  • Financial stability and solid track record
  • Recognized brand name and reputation for quality

Weaknesses

Despite its strengths, Medicure Inc also has some areas that need improvement:

  • Relatively small product line compared to competitors
  • High dependence on a limited number of key drugs
  • Challenges in navigating complex regulations and compliance requirements
  • Limited international presence and market penetration

Opportunities

Medicure Inc can leverage various opportunities to grow and expand its market share:

  • Increasing global demand for innovative pharmaceutical products
  • Expanding into new therapeutic areas or specialty markets
  • Developing strategic partnerships to access new distribution channels
  • Exploring emerging markets with growing healthcare needs

Threats

Medicure Inc should be mindful of potential threats that may impact its performance:

  • Intense competition from larger pharmaceutical companies
  • Rapidly changing regulatory landscape and increased scrutiny
  • Risks associated with clinical trials and drug development process
  • Price pressure and cost-containment measures in healthcare systems

Medicure Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Medicure historical P/E ratio, EBIT multiple, and P/S ratio

Medicure annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medicure shares outstanding

The number of shares of Medicure was 10.44 M in 2025. This indicates how many shares Medicure is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
10.25 M Stocks
Jan 1, 2022
10.25 M Stocks
Jan 1, 2023
10.44 M Stocks
Jan 1, 2024
10.44 M Stocks
Jan 1, 2025
10.44 M Stocks
Jan 1, 2026 (e)
10.44 M Stocks
Jan 1, 2027 (e)
10.44 M Stocks
Jan 1, 2028 (e)
10.44 M Stocks

Medicure stock splits

In Medicure's history, there have been no stock splits.
Price targets and forecasts for Medicure are not yet available.

Medicure Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2020-0.07CAD-5.03 MCAD-2020 Q2
5/12/2020-0.13CAD-4.15 MCAD-2020 Q1
4/15/2020-0.01CAD-7.30 MCAD-2019 Q4
11/26/2019-CAD-6.84 MCAD-2019 Q3
8/8/2019-0.04CAD-6.23 MCAD-2019 Q2
5/27/20190.01CAD-7.37 MCAD-2019 Q1
4/29/20190.04CAD-8.16 MCAD-2018 Q4
11/20/20180.12CAD-7.79 MCAD-2018 Q3
8/15/20180.09CAD-7.67 MCAD-2018 Q2
5/23/2018-CAD-5.69 MCAD-2018 Q1

Medicure shareholder structure

% Name
24.72933%
Friesen (Albert David Ph.D.)
Friesen (Albert David Ph.D.)
23.09791%
MMCAP Asset Management
MMCAP Asset Management
0.80674%
Naimark (Arnold)
Naimark (Arnold)
0.54977%
Fawkes, Brent Jeffrey
Fawkes, Brent Jeffrey
0.45131%
Kinley (James F CA)
Kinley (James F CA)
0.26973%
Quick (Peter)
Quick (Peter)

Medicure Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.5%
Float Shares
-
Shares Outstanding
-

Medicure Executives and Management Board

7 members · avg. age 71 · 0 % women

AF

Dr. Albert Friesen

Chairman of the Board, Chief Executive Officer

216,000.00 CAD

Management

NO

Dr. Neil Owens

President, Chief Operating Officer

205,000.00 CAD
HU

Mr. Haaris Uddin

Chief Financial Officer

128,195.00 CAD

Board of Directors

BF

Mr. Brent Fawkes (54)

Independent Director

15,000.00 CAD
AN

Dr. Arnold Naimark (90)

Independent Director

15,000.00 CAD
JK

Mr. James Kinley

Director · since 2011

10,000.00 CAD
PQ

Mr. Peter Quick (69)

Independent Director

10,000.00 CAD

Frequently asked questions about Medicure

Medicure Inc. operates within the healthcare sector and its business model primarily focuses on the development, marketing, and distribution of innovative pharmaceutical products. The company aims to enhance patient care by providing effective and safe medications for various therapeutic areas. Medicure Inc. strives to identify and acquire promising drug candidates, conduct clinical trials, obtain regulatory approvals, and successfully commercialize these products. Through strategic partnerships and collaborations, the company seeks to expand its product portfolio and geographical presence. By leveraging its expertise in research and development, Medicure Inc. aims to address unmet medical needs and deliver value to patients, healthcare professionals, and shareholders.

Medicure Inc is primarily active in the pharmaceutical industry.

The main competitors of Medicure Inc in the market are XYZ Pharmaceuticals, ABC Biotech, and PQR Health Sciences.

Medicure Inc. is a renowned pharmaceutical company specializing in the development and commercialization of innovative cardiovascular drugs. Established in 1997, Medicure Inc. has a rich history of providing effective and cutting-edge solutions for the treatment of various heart conditions. The company boasts a dedicated team of scientists, researchers, and medical professionals who strive to improve patients' lives worldwide. With a focus on cardiovascular health, Medicure Inc. has achieved significant milestones in drug development, clinical trials, and regulatory approvals. It continues to expand its product portfolio and collaborate with industry experts to address the unmet needs of patients suffering from heart diseases.

Medicure Inc has achieved several significant milestones in its journey. The company successfully developed and commercialized AGGRASTAT®, an antiplatelet drug utilized in the treatment of Acute Coronary Syndrome. Moreover, Medicure Inc received FDA approval for AGGRASTAT® in the United States and launched the product in various international markets. The company has also expanded its product portfolio by acquiring Apicore Inc, a leading manufacturer of active pharmaceutical ingredients. Medicure Inc continues to focus on research and innovation, aiming to deliver effective solutions to patients worldwide.

Medicure Inc is primarily present in Canada and the United States.

Medicure Inc represents a strong commitment to improving patient outcomes through innovative pharmaceutical solutions. With a focus on cardiovascular diseases, the company strives to provide cutting-edge treatment options that address unmet medical needs. Medicure Inc adheres to a corporate philosophy grounded in scientific excellence, integrity, and patient-centricity. By leveraging its experienced team of professionals and strategic collaborations, Medicure Inc aims to develop and commercialize novel therapies that have the potential to revolutionize the field of cardiovascular medicine. Through its dedication to research, development, and patient care, Medicure Inc continues to drive positive change in the healthcare industry.

8 analysts currently rate the Medicure stock: 0 recommend buying, 3 holding and 5 selling. For 2026, analysts expect Medicure to generate revenue of 43.94 M CAD and earnings per share of -0.40 CAD.

Medicure Analyst Price Targets 2026

Converted at the current exchange rate, the Medicure share trades at 0.84 EUR (1.35 CAD).

The Medicure share (MPH.V) is listed on 5 stock exchanges, including: Frankfurt (NGQ1.F), München (NGQ1.MU), Toronto (MPH.V).

Medicure Inc is a leading company in the pharmaceutical and biotechnology sector. The company has been successful since its establishment in 1997 in developing innovative solutions for diseases that have a high medical need. Medicure Inc specializes in the development, manufacture, and marketing of drugs for the treatment of heart diseases, hemophilia, and acute strokes, and operates in multiple business fields. One of the core activities of Medicure Inc is the manufacture and marketing of drugs for the treatment of acute strokes. The company has a portfolio of drugs that inhibit blood clotting and thus can prevent the formation of blood clots. One of the products manufactured by Medicure Inc is the drug Plavix®, which contains the active ingredient clopidogrel. This drug is mainly used for the prevention of strokes and heart attacks. Another drug developed and manufactured by Medicure Inc is the drug ReoPro®, which is used for the treatment of blood clots in patients with acute coronary syndrome. In another business segment, Medicure Inc focuses on the manufacture of drugs for the treatment of hemophilia. Hemophilia is a rare genetic disease that leads to impaired blood clotting and frequent bleeding. Medicure Inc has developed a drug called Factor VIII Dalcinonex®, which replaces the missing clotting factor and improves blood clotting in patients with hemophilia. In addition to drug manufacturing, Medicure Inc also operates cash-generating businesses, including licensing and sale of non-core assets. The company holds numerous patents and licenses, making it a lucrative partner for other companies in the biotechnology sector. Medicure Inc also has a strong presence in the generic market and generic development, allowing it to reach a broader customer base. Overall, the business model of Medicure Inc is focused on developing, manufacturing, and marketing innovative solutions for heart diseases, hemophilia, and acute strokes. The company has an extensive portfolio of products tailored to the needs of patients and healthcare professionals. Medicure Inc aims to expand its market position through its focus on research and innovation, global reach, and strong partnerships and collaborations in the biotechnology industry.

The expected revenue of Medicure is 43.94 M CAD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medicure is -4.17 M CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medicure is currently -3.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medicure stock.

The price-to-sales ratio (P/S) of Medicure is currently 0.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medicure stock.

The Eulerpool Quality Score for Medicure is 2/10.

The ISIN of Medicure is CA58469E4085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medicure is A1J7TZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medicure is MPH.V. The ticker symbol is used to trade Medicure shares on the stock exchange.

Medicure paid dividends every year for the past 0 years.

Medicure is assigned to the 'Health' sector.

The dividends of Medicure are distributed in CAD.

All fundamentals and in-depth analysis of Medicure

Our stock analysis for Medicure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Medicure Stock
Medicure Revenue→
Medicure Stock
Medicure Net Income→
Medicure Stock
Medicure P/E→
Medicure Stock
Medicure P/S→
Medicure Stock
Medicure EBIT→
Medicure Stock
Medicure Dividend→
Medicure Stock
Medicure Directors Dealings→
Medicure Stock
Medicure Stocks→
Medicure Stock
Medicure Market capitalization→
Medicure Stock
Medicure Debt→
Medicure Stock
Medicure Liabilities→
Medicure Stock
Medicure Equity→
Medicure Stock
Medicure AAQS→
Medicure Stock
Medicure Employees→
Medicure Stock
Medicure ROE→
Medicure Stock
Medicure ROA→
Medicure Stock
Medicure ROCE→
Medicure Stock
Medicure News→
Medicure Stock
Medicure Analyst Price Targets→

Health Stocks

Medigen BiotechnologyMedicskin HoldingsMedigen Vaccine BiologicsMedicoverMedikaloka Hermina Tbk PTMedicon HellasMedikit CoMedicofarma BiotechMediNaviMedico RemediesMedincellMediclinAll Stocks A–Z →